标题
Drugs and Clinical Approaches Targeting the Antiapoptotic Protein: A Review
作者
关键词
-
出版物
Biomed Research International
Volume 2019, Issue -, Pages 1-6
出版商
Hindawi Limited
发表日期
2019-09-30
DOI
10.1155/2019/1212369
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Ibrutinib and Venetoclax for First-Line Treatment of CLL
- (2019) Nitin Jain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions
- (2019) Kirsten Fischer et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase I study of AT-101, a BH3 mimetic, in combination with paclitaxel and carboplatin in solid tumors
- (2019) Mark N. Stein et al. INVESTIGATIONAL NEW DRUGS
- Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study
- (2018) Courtney D DiNardo et al. LANCET ONCOLOGY
- Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial
- (2018) Jeffrey A Jones et al. LANCET ONCOLOGY
- S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth
- (2018) Patrick Casara et al. Oncotarget
- Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial
- (2018) Paula Cramer et al. LANCET ONCOLOGY
- Targeting Mcl-1 and other Bcl-2 family member proteins in cancer therapy
- (2018) Ryuji Yamaguchi et al. PHARMACOLOGY & THERAPEUTICS
- NOXA genetic amplification or pharmacologic induction primes lymphoma cells to BCL2 inhibitor-induced cell death
- (2018) Yuxuan Liu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Current perspectives in fragment-based lead discovery (FBLD)
- (2017) Bas Lamoree et al. Essays in Biochemistry
- Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
- (2017) Matthew S. Davids et al. JOURNAL OF CLINICAL ONCOLOGY
- Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax
- (2017) Joel D. Leverson et al. Cancer Discovery
- A phase II trial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancer
- (2016) Paul L. Swiecicki et al. INVESTIGATIONAL NEW DRUGS
- Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
- (2016) M. Konopleva et al. Cancer Discovery
- Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+lymphoid malignancies
- (2015) Andrew W. Roberts et al. BRITISH JOURNAL OF HAEMATOLOGY
- Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors
- (2015) Anthony W. Tolcher et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study
- (2015) Anthony W. Tolcher et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
- (2015) Shundong Cang et al. Journal of Hematology & Oncology
- A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia
- (2015) Thomas J. Kipps et al. LEUKEMIA & LYMPHOMA
- A Phase II, Multicenter, Open-Label Study of Obatoclax Mesylate in Patients With Previously Untreated Myelodysplastic Syndromes With Anemia or Thrombocytopenia
- (2014) Martha L. Arellano et al. Clinical Lymphoma Myeloma & Leukemia
- A phase I/II study of the pan Bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell lymphoma
- (2014) André Goy et al. LEUKEMIA & LYMPHOMA
- A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer
- (2013) William R. Schelman et al. INVESTIGATIONAL NEW DRUGS
- Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial
- (2012) Patrick A. Ott et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer
- (2012) C. M. Rudin et al. CLINICAL CANCER RESEARCH
- Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors
- (2011) Leena Gandhi et al. JOURNAL OF CLINICAL ONCOLOGY
- Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
- (2011) Andrew W. Roberts et al. JOURNAL OF CLINICAL ONCOLOGY
- A Phase I Trial of Oblimersen Sodium in Combination With Cisplatin and 5-Fluorouracil in Patients With Advanced Esophageal, Gastroesophageal Junction, and Gastric Carcinoma
- (2010) Rachel Raab et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Phase I trial of oblimersen (Genasense®) and gemcitabine in refractory and advanced malignancies
- (2010) Peter S. Galatin et al. INVESTIGATIONAL NEW DRUGS
- Phase I/II Study of AT-101 with Topotecan in Relapsed and Refractory Small Cell Lung Cancer
- (2010) Rebecca Suk Heist et al. Journal of Thoracic Oncology
- 5-Year Survival in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia in a Randomized, Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen
- (2009) Susan O'Brien et al. JOURNAL OF CLINICAL ONCOLOGY
- AT-101, a small molecule inhibitor of anti-apoptotic Bcl-2 family members, activates the SAPK/JNK pathway and enhances radiation-induced apoptosis
- (2009) Shuraila F Zerp et al. Radiation Oncology
- ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
- (2008) C. Tse et al. CANCER RESEARCH
- Discovery of an Orally Bioavailable Small Molecule Inhibitor of Prosurvival B-Cell Lymphoma 2 Proteins
- (2008) Cheol-Min Park et al. JOURNAL OF MEDICINAL CHEMISTRY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search